B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.

Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, supportive care, grading, or real-world mitigation strategies. Tocilizumab and ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

Phase III results put obinutuzumab in line for approval ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

B cells are a central component of the adaptive immune system, responsible for recognising pathogens and producing antibodies that neutralise infections. Their development, activation and ...

Regulatory B cells (Breg) have emerged as pivotal modulators of the immune system, mediating immune tolerance and preventing excessive inflammatory responses. These specialised B cells exert their ...

Zenas BioPharma, Inc. (ZBIO) is gearing up to report data from several of its ongoing studies using its differentiated B-Cell targeting drug obexelimab for autoimmune disorders. In particular, the ...

Please provide your email address to receive an email when new articles are posted on . Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward ...